Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
YAP (Yes-associated protein 1) and TAZ (Transcriptional coactivator with PDZ-binding motif) are closely related transcriptional coactivators that function as downstream effectors of the Hippo tumor suppressor pathway.[1][2][3] These proteins lack intrinsic DNA-binding domains and instead regulate gene expression by physically associating with DNA-binding transcription factors, most notably the TEAD family of transcription factors (TEAD1-4), to activate genes involved in cell proliferation, growth, and survival.[1][2] Their activity is regulated by Hippo pathway signaling: when the pathway is active, YAP/TAZ are phosphorylated and sequestered in the cytoplasm; when inactive, they translocate to the nucleus to act as transcriptional coactivators.[1][2][3] YAP and TAZ are frequently overexpressed and oncogenic in multiple cancer types including breast, lung, ovarian, colorectal, and prostate cancers, where they promote malignant proliferation, invasion, metastasis, and chemotherapy resistance.[1][3] However, these proteins also possess context-dependent tumor-suppressive functions when bound to different partner transcription factors such as p73, whereby they can induce apoptosis in response to DNA damage.[1] Currently, there are no FDA-approved drugs specifically targeting YAP/TAZ, but disrupting their interaction with TEAD transcription factors represents an active therapeutic strategy under development.[5]
Acts as a transcriptional coactivator by binding to DNA-binding transcription factors (primarily TEAD family members) to regulate target gene expression. Lacks intrinsic DNA-binding activity and requires partner transcription factors. Regulated by the Hippo pathway through phosphorylation and cytoplasmic sequestration. Competitive inhibition of TEAD/VGLL4 repressor complexes. Recruitment of SWI/SNF complexes and chromatin remodelers via partner proteins.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Yes-associated protein 1 (YAP) and Transcriptional coactivator with PDZ-binding motif (TAZ) (YAP1 (or YAP); TAZ (or WWTR1)).